Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Comparison of triple anti-platelet therapy and dual anti-platelet therapy in patients with acute myocardial infarction who had no-reflow phenomenon during percutaneous coronary intervention.

Lee KH, Ahn Y, Kim SS, Rhew SH, Jeong YW, Jang SY, Cho JY, Jeong HC, Park KH, Yoon NS, Sim DS, Yoon HJ, Kim KH, Hong YJ, Park HW, Kim JH, Cho JG, Park JC, Jeong MH, Cho MC, Kim CJ, Kim YJ; KAMIR (Korea Acute Myocardial Infarction Registry) Investigators.

Circ J. 2013;77(12):2973-81. Epub 2013 Aug 29.

2.

Triple vs. dual antiplatelet therapy in patients with acute myocardial infarction and renal dysfunction.

Choi YH, Suh SH, Choi JS, Kim CS, Sim DS, Bae EH, Lim SY, Ma SK, Jeong MH, Kim SW; Korea Acute Myocardial Infarction Registry Investigators.

Circ J. 2012;76(10):2405-11. Epub 2012 Jul 3.

3.

Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.

Chen KY, Rha SW, Li YJ, Poddar KL, Jin Z, Minami Y, Wang L, Kim EJ, Park CG, Seo HS, Oh DJ, Jeong MH, Ahn YK, Hong TJ, Kim YJ, Hur SH, Seong IW, Chae JK, Cho MC, Bae JH, Choi DH, Jang YS, Chae IH, Kim CJ, Yoon JH, Chung WS, Seung KB, Park SJ; Korea Acute Myocardial Infarction Registry Investigators.

Circulation. 2009 Jun 30;119(25):3207-14. doi: 10.1161/CIRCULATIONAHA.108.822791. Epub 2009 Jun 15.

4.

[Short-term outcomes of triple antiplatelet therapy after percutaneous coronary intervention].

Han YL, Su QF, Li Y, Wang SL, Jing QM, Ma YY, Wang ZL, Wang DM, Luan B.

Zhonghua Yi Xue Za Zhi. 2006 Apr 25;86(16):1093-6. Chinese.

PMID:
16796832
5.
6.

Comparison of 600 versus 300-mg Clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary coronary angioplasty.

Mangiacapra F, Muller O, Ntalianis A, Trana C, Heyndrickx GR, Bartunek J, Vanderheyden M, Wijns W, De Bruyne B, Barbato E.

Am J Cardiol. 2010 Nov 1;106(9):1208-11. doi: 10.1016/j.amjcard.2010.06.044.

PMID:
21029814
7.

What is the optimal duration of triple anti-platelet therapy in patients with acute myocardial infarction undergoing drug-eluting stent implantation?

Park KH, Jeong MH, Lee MG, Ko JS, Sim DS, Yoon NS, Yoon HJ, Hong YJ, Kim KH, Park HW, Kim JH, Ahn Y, Cho JG, Park JC, Kang JC.

J Cardiol. 2011 Jan;57(1):53-60. doi: 10.1016/j.jjcc.2010.10.002. Epub 2010 Dec 10.

8.

Usefulness of transient and persistent no reflow to predict adverse clinical outcomes following percutaneous coronary intervention.

Chan W, Stub D, Clark DJ, Ajani AE, Andrianopoulos N, Brennan AL, New G, Black A, Shaw JA, Reid CM, Dart AM, Duffy SJ; Melbourne Interventional Group Investigators.

Am J Cardiol. 2012 Feb 15;109(4):478-85. doi: 10.1016/j.amjcard.2011.09.037. Epub 2011 Dec 15.

PMID:
22176999
9.

Comparison of Triple antiplatelet therapy and dual antiplatelet therapy in patients at high risk of restenosis after drug-eluting stent implantation (from the DECLARE-DIABETES and -LONG Trials).

Lee SW, Chun KJ, Park SW, Kim HS, Kim YH, Yun SC, Kim WJ, Lee JY, Park DW, Lee CW, Hong MK, Rhee KS, Chae JK, Ko JK, Park JH, Lee JH, Choi SW, Jeong JO, Seong IW, Jon S, Cho YH, Lee NH, Kim JH, Park SJ.

Am J Cardiol. 2010 Jan 15;105(2):168-73. doi: 10.1016/j.amjcard.2009.08.667. Epub 2009 Dec 3.

PMID:
20102913
10.

Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoProGive Similar Efficacy Outcome Trial (TARGET).

Chan AW, Moliterno DJ, Berger PB, Stone GW, DiBattiste PM, Yakubov SL, Sapp SK, Wolski K, Bhatt DL, Topol EJ; TARGET Investigators.

J Am Coll Cardiol. 2003 Oct 1;42(7):1188-95.

11.

[The effects of post coronary stenting triple antiplatelet therapies on platelet functions].

Han YL, Su QF, Li Y, Kang J, Yan CH, Wang SL.

Zhonghua Nei Ke Za Zhi. 2006 Aug;45(8):635-8. Chinese.

PMID:
17074146
13.

Long-term effectiveness and safety of triple versus dual antiplatelet therapy after percutaneous coronary intervention for unprotected left main coronary artery disease.

Lee HJ, Yu CW, Hwang HK, Choi RK, Park JS, Li H, Ro YM.

Coron Artery Dis. 2013 Nov;24(7):542-8. doi: 10.1097/MCA.0b013e328363abbd.

PMID:
23994880
14.

A comparative evaluation of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention.

Dasbiswas A, Rao MS, Babu PR, Vijayvergiya R, Nayak R, Dani S, Tyagi S, Hiremath S, Patel T, Alexander T, Prakash VS, Singh DP, Yadav MK, Pathak K, Srivastava A.

J Assoc Physicians India. 2013 Feb;61(2):114-6, 126.

PMID:
24471250
15.

Efficacy and safety of triple antiplatelet therapy in obese patients undergoing stent implantation.

Gao W, Zhang Q, Ge H, Guo Y, Zhou Z.

Angiology. 2013 Oct;64(7):554-8. doi: 10.1177/0003319712474113. Epub 2013 Jan 27.

PMID:
23359782
16.

Efficacy and safety of triple-antiplatelet therapy after percutaneous coronary intervention: a meta-analysis.

Zhang Y, Tang HQ, Li J, Fu ZX.

Chin Med J (Engl). 2013;126(9):1750-4.

PMID:
23652062
17.
18.

Effect of tirofiban plus clopidogrel and aspirin on primary percutaneous coronary intervention via transradial approach in patients with acute myocardial infarction.

Fu XH, Hao QQ, Jia XW, Fan WZ, Gu XS, Wu WL, Hao GZ, Li SQ, Jiang YF, Geng W.

Chin Med J (Engl). 2008 Mar 20;121(6):522-7.

PMID:
18364139
19.

Efficacy of high-dose clopidogrel treatment (600 mg) less than two hours before percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes.

Feldman DN, Fakorede F, Minutello RM, Bergman G, Moussa I, Wong SC.

Am J Cardiol. 2010 Feb 1;105(3):323-32. doi: 10.1016/j.amjcard.2009.09.034. Epub 2009 Dec 22.

PMID:
20102943
20.

Supplemental Content

Support Center